Alzheimer’s drug development is shifting. For decades, the field revolved around amyloid. Today, researchers are exploring the deeper biology of aging that fuels the disease itself. Novo Nordisk’s latest phase 3 Evoke and Evoke+ trials mark a critical moment in that shift—even though the topline results did not meet their primary endpoints.
Novo Nordisk tested oral semaglutide, a GLP-1–based therapy commonly associated with metabolic diseases, in people with early-stage Alzheimer’s. The idea: target metabolic dysfunction, one of the key pathways implicated in neurodegeneration.
What the Phase 3 Results Show?
The trials did not hit their primary goals. Still, the data points toward something important: a broader move to target Alzheimer’s biology beyond amyloid.
Dr. Howard Fillit, Co-Founder and CSO of the Alzheimer’s Drug Discovery Foundation (ADDF), calls it a “fundamental shift.”
Early Signals Worth Noting
- Novo Nordisk observed improvements in Alzheimer’s-related biomarkers, despite missing endpoints.
- These findings hint that semaglutide may still have value—especially as part of combination therapy.
- Today’s anti-amyloid drugs slow cognitive decline by roughly 30%. The remaining 70% demands new pathways and new drug classes.
- The Evoke programs represent momentum toward approaches similar to cancer therapy: multiple mechanisms working together.
More detailed findings will be presented at the CTAD conference on December 3, a key moment for researchers watching this space.
Why the Metabolic Pathway Still Matters?
Even with mixed topline results, metabolic dysfunction remains a compelling target.
The ADDF helped pave this pathway more than a decade ago. In 2011, the foundation invested nearly $1 million in a phase 2 study of liraglutide, an earlier GLP-1 drug. That work advanced the understanding of GLP-1 activity in the brain and helped attract major funding from Novo Nordisk and GE HealthCare.
In simple terms: without these early bets, today’s phase 3 trials wouldn’t exist.
A Push Toward Precision Medicine in Alzheimer’s
Dr. Fillit underscores a growing truth in neurology: Alzheimer’s isn’t one disease. It’s a spectrum of overlapping biological failures.
What the Future Looks Like
- Therapies tailored to a patient’s unique biomarker profile.
- Combination regimens targeting multiple pathways simultaneously.
- Earlier intervention guided by better biomarkers, imaging tools, and predictive tests.
More than 70% of the current Alzheimer’s pipeline targets novel pathways—clear evidence that the field is moving into a new era of science.
Looking Ahead: CTAD and Beyond
Further topline data from Evoke and Evoke+ will be presented at CTAD in San Diego, offering deeper clarity on biomarkers, safety, and the therapy’s role in combination approaches.
Regardless of the primary endpoint outcome, the completion of these trials matters. They reflect rising momentum behind treatments aimed at the disease’s root biology—not just its end-stage protein deposits.
About the Alzheimer’s Drug Discovery Foundation (ADDF)
Founded in 1998 by Leonard A. and Ronald S. Lauder, the ADDF is the only public charity solely devoted to accelerating drug development for Alzheimer’s. Using a venture-philanthropy model, the foundation funds cutting-edge research across academia and biotech.
Fast Facts
- $370 million awarded to date.
- 765 programs funded across 21 countries.
- Played a key role in bringing the first Alzheimer’s PET scan (Amyvid®) and blood test (PrecivityAD®) to market.
- Continues to drive innovation in biomarkers, prevention, and next-generation therapies.
